Please select the option that best describes you:
Would you recommend adjuvant nivolumab for patients with upper tract urothelial cancer?
The forest plot from CheckMate 274 did not show a benefit for such patients?
How would you select between adjuvant chemotherapy and adjuvant nivolumab?
Answer from: Medical Oncologist at Academic Institution
For any patient with upper tract UC who is eligible for cisplatin, adjuvant cisplatin based chemotherapy would be the preferred standard of care approach. This would be supported by results from the POUT trial where patients treated with cisplatin were deprived significant DFS benefit compared to su...
Sign in or Register to read more